Germany-based biopharmaceutical company Probiodrug secured €15m ($19.2m) in funding on Wednesday from investors including Biogen Idec New Ventures, a corporate venturing unit belonging to pharmaceutical corporation Biogen Idec, and biotechnology investment company BB Biotech.
Also investing in the round were Edmond de Rothschild Investment Partners, which acts as a division of the Edmond de Rothschild banking group, venture capital (VC) firms Life Science Partners and TVM Capital, investment holding company HBM BioVentures, investment fund Goodvent/ IBG and new investor…
